A Study to Investigate the Long Term Safety, Tolerability And Effectiveness of Pf-02545920 in Subjects with Huntington's Disease Who Completed Study A8241021


About this study

The purpose of this study is an extension following study A8241021 to assess the long-term safety, tolerability and effectiveness of PF-02545920   in patients with Huntington's disease. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria

  • Must have completed study A8241021
  • Diagnosis of Huntington's disease, including ≥ 36 CAG repeats


Exclusion Criteria

  • Significant neurological disorder other than Huntington's disease
  • WBC ≤ 3500/mm3 
  • ANC ≤ 2000/mm3 
  • History of neutropenia or myeolo-proliferative disorders
  • Any drug related significant adverse event experienced during study A8241021 which were not approved as acceptable for enrollment in A8241022

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

John Caviness, M.D.

Closed for enrollment

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer